当前位置：
X-MOL 学术
›
Asia Pac. J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer
Asia-Pacific Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2022-06-10 , DOI: 10.1111/ajco.13803 Daijiro Harada 1 , Atsushi Shimonishi 1 , Kazuhiko Saeki 1 , Takashi Ninomiya 1 , Hiromitsu Kanzaki 2 , Kei Nagasaki 2 , China Ogura 3 , Yoko Tsutsui 3 , Kazuhiro Kojin 3 , Yasushi Hamamoto 2 , Toshiyuki Kozuki 1
Asia-Pacific Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2022-06-10 , DOI: 10.1111/ajco.13803 Daijiro Harada 1 , Atsushi Shimonishi 1 , Kazuhiko Saeki 1 , Takashi Ninomiya 1 , Hiromitsu Kanzaki 2 , Kei Nagasaki 2 , China Ogura 3 , Yoko Tsutsui 3 , Kazuhiro Kojin 3 , Yasushi Hamamoto 2 , Toshiyuki Kozuki 1
Affiliation
|
Durvalumab (Durva) administration after chemoradiation therapy (CRT) in locally advanced non-small-cell lung cancer (NSCLC) is the standard of care, associated with relatively prolonged progression-free (PFS) and overall survival. However, pneumonitis occurs in 73.6% of Japanese patients. This retrospective study aimed to identify factors associated with Durva efficacy and safety, specifically, the risk of pneumonitis.
中文翻译：
放化疗后早期给予 durvalumab 会增加局部晚期非小细胞肺癌患者患肺炎的风险
Durvalumab (Durva) 在局部晚期非小细胞肺癌 (NSCLC) 放化疗 (CRT) 后给药是标准治疗，与相对延长的无进展 (PFS) 和总生存期相关。然而，73.6% 的日本患者患有肺炎。这项回顾性研究旨在确定与 Durva 疗效和安全性相关的因素，特别是肺炎的风险。
更新日期：2022-06-10
中文翻译：
放化疗后早期给予 durvalumab 会增加局部晚期非小细胞肺癌患者患肺炎的风险
Durvalumab (Durva) 在局部晚期非小细胞肺癌 (NSCLC) 放化疗 (CRT) 后给药是标准治疗，与相对延长的无进展 (PFS) 和总生存期相关。然而，73.6% 的日本患者患有肺炎。这项回顾性研究旨在确定与 Durva 疗效和安全性相关的因素，特别是肺炎的风险。
京公网安备 11010802027423号